Business Context and Reporting Period
Filing identity: The supplied filing is Catalyst Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2021; this does not match the request metadata naming Gyre Therapeutics, Inc. Investors should verify the issuer before relying on this summary. Catalyst is a clinical-stage biopharmaceutical company developing engineered protease candidates for bleeding and complement-related disorders. It had no products approved for sale and reported no product-sale revenue.
Key programs included MarzAA, in a Phase 3 trial for episodic bleeding in hemophilia A or B with inhibitors; DalcA, a hemophilia B candidate; and complement programs including CB 4332 and Biogen-licensed CB 2782-PEG.
Financial Results and Liquidity
Amounts below are in millions of dollars except per-share data. The filing reports three- and six-month results through June 30, 2021, compared with the same periods in 2020.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| License and collaboration revenue | $1.13 | $1.66 | $2.60 | $18.02 |
| Research and development expense | $15.39 | $12.91 | $32.40 | $26.17 |
| General and administrative expense | $4.52 | $4.37 | $9.93 | $8.06 |
| Operating loss | $(19.91) | $(17.36) | $(42.35) | $(22.43) |
| Net loss | $(19.93) | $(17.25) | $(42.37) | $(21.30) |
| Basic and diluted net loss per share | $(0.64) | $(0.96) | $(1.42) | $(1.31) |
Revenue was primarily collaboration reimbursement from Biogen in 2021. The 2020 six-month comparison included a $15.0 million Biogen upfront license payment. Collaboration revenue was approximately offset by related collaboration costs; the filing does not present a meaningful consolidated operating margin.
At June 30, 2021, cash and cash equivalents were $73.6 million and short-term investments were $12.9 million, totaling $86.5 million in cash, cash equivalents and investments. Current assets were $96.8 million and current liabilities were $15.6 million. Total liabilities were $16.6 million, including operating lease liabilities; the filing does not report debt borrowings. Accumulated deficit was $357.1 million.
Cash used in operating activities was $44.5 million for the first six months, versus $19.9 million in 2020. Investing activities provided $38.3 million, mainly from investment maturities; financing activities provided $49.5 million, mainly from the 2021 stock offering. Management said existing cash, cash equivalents and investments were expected to fund requirements for at least 12 months from the filing date, while cautioning that its assumptions could prove wrong.
Material Changes Versus the Prior Comparable Period
- Six-month net loss nearly doubled to $42.4 million from $21.3 million, while total revenue fell 86% to $2.6 million, largely because the prior-year period included the Biogen upfront payment.
- Six-month R&D expense rose 24% to $32.4 million; management cited higher personnel and facilities, preclinical research, and clinical manufacturing costs. G&A increased 23% to $9.9 million, primarily from personnel-related costs and professional services.
- In the first quarter, Catalyst sold 9.185 million shares at $5.75 per share and received approximately $49.3 million net. Common shares outstanding rose to 31.35 million at June 30, 2021 from 22.10 million at December 31, 2020.
- Cash and investments increased to $86.5 million from $81.9 million at year-end 2020, with the increase supported by the equity offering and investment maturities.
Outlook, Risks, Contingencies and Unusual Items
- Management expected losses and significant expenses to continue for several years, with R&D expense expected to increase as programs advance. The company had no commercial product revenue and said future Biogen milestones or royalties were uncertain.
- COVID-19 had delayed enrollment in the MAA-304 and MAA-202 trials and could further disrupt trial enrollment, manufacturing, supply chains and development timelines. Catalyst reported that required MarzAA supplies for those studies had been manufactured.
- Management planned a 2021 report to the MarzAA Phase 3 Data and Safety Monitoring Board. Catalyst commenced enrollment in CFI screening and natural-history studies in July 2021 and anticipated a CB 4332 Phase 1/2 study in 2022. It planned to discuss a DalcA Phase 3 design with FDA and was seeking a partner.
- Firm AGC manufacturing work orders for MarzAA and DalcA totaled $19.7 million; $7.0 million remained payable at quarter-end. A July 2021 subsequent event disclosed additional clinical-services agreements with payments of up to $3.2 million for MarzAA and $6.5 million for CFI studies; Catalyst could terminate them, subject to accrued service and wind-down costs.
- The company disclosed no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting.
- Additional funding may be needed; equity financing could dilute shareholders, debt could impose repayment and covenant obligations, and collaborations or licensing could require relinquishing rights. The company said financing might not be available on acceptable terms, or at all.
Most Important Facts for Investors to Verify
- Confirm the filing is for Catalyst Biosciences, not Gyre Therapeutics, and check the intended issuer and reporting period.
- Track operating cash use against the $86.5 million cash-and-investment balance and assess the assumptions behind management’s stated 12-month runway.
- Monitor MarzAA enrollment and trial progress, including the effects of COVID-19, and verify subsequent regulatory and clinical updates.
- Assess the timing, costs and development prospects of CB 4332 and DalcA, including the planned FDA discussions and DalcA partnering efforts.
- Review the company’s financing needs, potential dilution and remaining manufacturing and clinical-services commitments.